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Aloe Emodin Induces Apoptosis in ER+-breast Cancer Cells; 
MCF-7 through IGF-1R Signalling Pathway
(Aloe Emodin Mengaruh Apoptosis dalam Sel Kanser Payu Dara ER+; MCF-7
 melalui Tapak Jalan Pengisyaratan IGF-1R)
INDAH MOHD AMIN, ROZIANA KAMALUDIN, SWEE KEONG YEAP, MOHAMAD RODI ISA, 
NIK MOHD MAZUAN NIK MOHD ROSDY, ROSFAIIZAH SIRAN, SITI HAMIMAH SHEIKH ABDUL KADIR 
& NARIMAH ABDUL HAMID HASANI*
ABSTRACT
Two-third of breast cancer patients expressed estrogen receptors (ER)s and received endocrine treatment with established 
anti-estrogens such as tamoxifen. But the action and acquired resistance during treatment are largely unknown. In 
contrary, phytochemicals are more selective and less cytotoxic to normal cells. Accordingly, we found aloe emodin, an 
anthraquinone to inhibit the proliferation of ER+-breast cancer cells, MCF-7 with IC50 of 80 µM, but not affecting control 
breast cells, MCF-10A. Tamoxifen was non-selective to both cells with IC50 of 27 and 38 μM, respectively. Thus, we 
aimed to investigate the anti-proliferative mechanism of aloe emodin on MCF-7 and its underlying signalling compared 
to tamoxifen. Cells were treated separately with aloe emodin and tamoxifen at respective IC50 for 72 h. Apoptosis was 
determined using Annexin V-FITC/PI staining. The expression of insulin-like growth factor-1 receptor (IGF-1R), insulin-
like growth factor binding protein (IGFBP)-2 and B-raf gene was investigated using QuantiGene 2.0 Plex assay. Paired-
student t-test and ANOVA test were used to compare between untreated and treated cells on the measured parameters. Each 
treatment was conducted in triplicate and repeated three times. Significance was set at p<0.05. The presences of early 
and late apoptosis in MCF-7 were seen in both treatments. All target genes were down regulated. The anti-proliferation 
effect of aloe emodin on MCF-7 is similar with tamoxifen which mediates inhibition of IGF-1R signalling pathway. This 
suggests aloe emodin as a potential anti-cancer agent to be used in combined anti-estrogen therapy to enhance its 
efficacy in ER+-breast cancer treatment. 
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ABSTRAK
Dua-pertiga pesakit kanser payu dara mengekspresi reseptor estrogen (RE) dan menerima rawatan endokrin dengan 
anti-estrogen seperti tamoksifen. Tetapi, tindakan dan kerentanan perolehan terhadap rawatan ini masih belum difahami. 
Sebaliknya, fito-kimia didapati lebih selektif dan kurang memberi kesan toksik kepada sel normal. Selanjutnya, kajian 
kami mendapati aloe emodin, sejenis antrakuinon berjaya merencat proliferasi sel kanser payu dara ER+, MCF-7 dengan 
IC50 80 µM, tanpa memberi kesan toksik kepada sel payu dara normal, MCF-10A. Sebaliknya, tamoksifen adalah tidak 
selektif kepada kedua-dua sel dengan IC50 masing-masing 27 dan 38 µM. Oleh itu, penyelidikan ini dijalankan untuk 
mengkaji mekanisme anti-proliferasi dan laluan pengisyaratan transduksi aloe emodin terhadap MCF-7 berbanding dengan 
tamoksifen. Sel diaruhkan dengan aloe emodin dan tamoksifen secara berasingan pada IC50 selama 72 jam. Apoptosis 
ditentukan dengan ujian Annexin V-FITC/PI pewarnaan. Pengekspresan gen-gen faktor tumbesaran-1 reseptor (IGF-1R) 
seperti-insulin, faktor tumbesaran pengikat protein (IGFBP)-2 seperti-insulin dan B-raf ditentukan menggunakan asai 
Plex QuantiGene 2.0. Ujian-T pelajar-berpasangan dan ANOVA digunakan untuk membandingkan antara parameter sel 
teraruh dan kawalan. Setiap perlakuan dijalankan sebanyak tiga kali dan diulang tiga kali. Tahap signifikan ditetapkan 
pada p<0.05. Tanda-tanda awal dan akhir apoptosis di MCF-7 diperhatikan pada kedua-dua aruhan. Ketiga-tiga gen 
diekspreskan kurang daripada paras normal. Kesan anti-proliferasi aloe emodin terhadap MCF-7 adalah bersamaan 
dengan tamoksifen iaitu melalui perencatan tapak jalan pengisyaratan tranduksi IGF-1R. Kajian ini mencadangkan aloe 
emodin berpotensi sebagai agen anti-kanser yang boleh digunakan sebagai rawatan gabungan dengan terapi anti-
estrogen yang sedia ada, bertujuan untuk meningkatkan efikasi rawatan tersebut.
Kata kunci: Aloe emodin; apoptosis; IGF-1R; MCF-7
INTRODUCTION
Breast cancer is the most frequent type of cancer (18.1%) 
with an occurrence of 32.1% among Malaysian women as 
compared with other type of cancers (Dahlui et al. 2011). Its 
incidence and death among women remain a major concern 
not only for Asian countries but also worldwide. Currently, 
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tamoxifen served as primarily systemic action for ER+-
breast cancer patients. Unfortunately, its effectiveness is 
limited as advanced stage patients’ progresses to a resistant 
phenotype (Dorssers et al. 2001). Despite its significant 
contribution in clinical setting, almost all patients with 
meta-static stage ultimately relapsed from their disease 
and are fatal (Ring & Dowsett 2004), thus emphasizing the 
importance of searching for a new chemotherapy regimens. 
Recently, aloe emodin has been recommended as a 
potential natural source of chemotherapeutic agents due to 
its cytotoxicity on several cancer cells, such as prostate (Lin 
et al. 2006), colon (Suboj et al. 2012) and hepatoma (Lu et 
al. 2007). The capacity of aloe emodin to induce apoptosis 
in these cells through several mechanisms has been well 
documented. Although there is a significant relationship 
between apoptosis and aloe emodin, its induction in ER+-
breast cancer cells has not been identified. Our findings 
have shown that unlike tamoxifen, aloe emodin selectively 
inhibited the proliferation of ER+-breast cancer cells, MCF-7 
in a time and dose dependent manner (Amin et al. 2013), 
without affecting normal breast cells, MCF-10A. However 
the mechanism underlying the anti-cancer activity remains 
unclear. 
 The insulin-like growth factor (IGF)-2/insulin-like 
growth factor-1 receptor (IGF-1R) signalling pathway 
has been suggested to play a causal role in anti-estrogen 
resistance of breast cancer cells (Zhang et al. 2011). IGF-1R 
belongs to the receptor tyrosine kinase family. Upon binding 
of IGFs to their receptors, a series of phosphorylation events 
occurs. IGFs are positively regulated by 17β-estradiol, 
progesterone, prolactin and growth hormone for both 
normal breast development and breast cancer progression 
(Felice et al. 2013). The 17β-estradiol-ERα complex binds 
and activates IGF-1R directly. Vice versa, IGF signalling 
enhances ERα activation in human breast cancer cells by 
phosphorylation (Yu et al. 2013). 17β-estradiol and IGF-1R 
synergistically enhances S phase entry in breast tumor cells 
(Yu et al. 2013).
 Tamoxifen directly competes with 17β-estradiol for 
ER binding in ER+-breast cancer cells (Surmacz 2000). 
It inhibits IGFs/IGF-1R-dependent growth through the 
down-regulation of IGF-1R (Chan et al. 2001), insulin-like 
growth factor binding protein (IGFBP)-2 (Juncker-Jensen 
et al. 2006) and plasma IGF-1 in breast cancer patients 
(Campbell et al. 2001). IGF-1R expression is up regulated in 
tamoxifen-resistant breast cancer cells (Massarweh et al. 
2008). In normal circulation and extracellular surrounding, 
IGFs bind with high affinity to IGFBP-1 and -2. IGFBP-2 is 
highly expressed in tamoxifen-resistant breast cancer cells 
(Juncker-Jensen et al. 2006). However, not many studies 
have been done on the interaction of IGFs and their IGFBPs, 
particularly in pathogenesis of cancer. Autophosphorylation 
of IGF-1R results in the activation of Ras/Braf/ERKs of the 
mitogen-activated protein kinase (MAPK) proliferative 
signalling cascade in ER+-breast epithelial cells (Zhang 
et al. 2011). B-raf, a serine-threonine-specific protein 
kinase is activated downstream of the small G-protein, 
Ras. It subsequently activates the MAPK extracellular 
signal-regulated kinases (MEKs) and extracellular signal-
regulated kinases (ERKs) of MAPK cascade (Holderfield et 
al. 2013). ERKs signalling pathway is crucial in transmitting 
proliferative signals generated by cell surface receptors 
and cytoplasmic signalling components into the nucleus 
(Holderfield et al. 2013; Zhang et al. 2011). B-raf mutation 
has been reported in 50-70% of human melanomas 
(Stones et al. 2013). Its expression is increased in acquired 
tamoxifen-resistant cells leading to agonist activity of 
tamoxifen (Jalili et al. 2012).
 IGF-1R signalling pathway and its key components 
may be directly involved in anti-estrogen resistance of 
ER+-breast cancer cells and suggested as potential targets 
in combined anti-estrogen therapy (Zhang et al. 2011). 
Therefore, the present study was carried out to investigate 
whether aloe emodin-induced apoptosis in breast cancer is 
mediated by IGF-1R signalling as reported in tamoxifen.
MATERIALS AND METHODS
CELLS AND TREATMENTS
ER+-breast cancer cells, MCF-7 were cultured in complete 
RPMI 1640 media, supplemented with 10% fetal bovine 
serum; 1% 10,000 IU penicillin and 10000 ug/mL 
streptomycin. Non-tumorigenic breast epithelial cells, 
MCF-10A used as control were maintained in complete 
DMEM high glucose media, supplemented with 5% horse 
serum, 20 ng/mL of epidermal growth factor, 0.5 mg/mL of 
hydrocortisone, 10 µg/mL insulin and 1% of penicillin and 
streptomycin. Both cells (American Type Cell Collection, 
USA) were routinely maintained as monolayer in humidified 
atmosphere of 5% CO2, at 37°C in T25 flask up to 70-
80% of confluence. For treatment, both aloe emodin and 
tamoxifen stock solutions were dissolved in dimethyl 
sulfoxide (DMSO) at 500 μM and kept at -20oC. These stock 
solutions were diluted in culture media so that the final 
concentration of DMSO in the culture media was <0.1%. 
Aloe emodin, tamoxifen and DMSO were purchased from 
Sigma Chemical Co (USA). The other chemicals used were 
from GIBCO Invitrogen (USA). T25 flask and disposable 
equipments were from Orange Scientific (Belgium). All 
the procedures followed were in accordance with current 
ethical standards.
VIABILITY ASSAY
Cells were seeded at 4 × 105 in 6-well plates and treated 
separately with aloe emodin and tamoxifen at respective 
IC50 of 80 and 27 μM up to 72 h. The IC50 were obtained 
from our previous results using MTT proliferation assay 
(Amin et al. 2013). As no IC50 was obtained for aloe emodin 
treatment in MCF-10A, its IC50 for MCF-7 was used. The 
morphology of cells was observed under Olympus inverted 
light microscope (Japan) at 100× magnification. Cells 
were then detached using accutase and stained with trypan 
blue dye at 10 fold dilution. A viable cell was presented 
with intact membrane and clear cytoplasm because it 
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was able to exclude the dye as compared to blue-colored 
cytoplasm of a non-viable cell. The cells were loaded 
into a hemocytometer (Marienfeld-Superior, Germany) 
and counted under Olympus inverted light microscope 
at 100× magnification. All chemicals used were from 
GIBCO Invitrogen (USA), while 6-well plate and disposable 
equipments were from Orange Scientific (Belgium). 
APOPTOSIS ASSAY
Cells were treated separately with aloe emodin and 
tamoxifen at respective IC50 concentrations for 72 h. 
Their effects on cell apoptosis were quantified using 
AnnexinV-FITC/PI assay kit following the manufacturer’s 
direction (BD Biosciences Pharmingen, USA). Annexin 
V has the ability to conjugate with phosphatidylserine, a 
component of membrane phospholipid that was exposed 
to the extracellular environment of membranes during 
early stage of apoptosis. Propidium iodide (PI) is a unique 
dye that was able to penetrate only the cells that have 
lost their membrane plasma integrity, thus making it as 
a good indicator during the late stage of apoptosis or 
necrosis. Both of these fluorescence dyes were measured 
using Calibur flow cytometry analyses (BD Biosciences 
Pharmingen, USA).
mRNA EXPRESSION ANALYSIS
The expression of IGF-1R, IGFBP-2 and B-raf was carried 
out using QuantiGene 2.0 Plex assay (Affymetrix, USA) 
that employed direct quantification on aloe emodin and 
tamoxifen-treated against untreated cells. Prior to the 
experiment, cells were seeded separately at 1 × 106 in T25 
flask (Orange Scientific, Belgium) with aloe emodin and 
tamoxifen at their respective IC50 concentrations. After 
72 h of incubation, cells were washed with phosphate 
buffered saline (Sigma Chemical Co, USA), detached and 
centrifuged. Cell pellets were resuspended and adjusted 
to approximately 1 × 106 cells per mL in culture media 
and kept at -20oC before used. The assay was conducted 
following the protocol described in QuantiGene 2.0 Plex 
User Manual. Approximately 2 × 104 cells were loaded into 
each of a 96 well-plate for the detection of the specific-
target RNA. Initially, cells were lysed to release the RNA. 
Capture beads were added to the lysis mixture and bind 
to the free RNA molecules. Next, the target-specific RNA 
was measured by mixing it with high stringent of cocktails 
which include capture extenders, label extenders and 
blocking probes. They bound to the region of RNA and 
selectively captured the target RNA by a series of complex 
hybridization. The hybridization step was carried out 
overnight at 55oC. These resulted in sandwich multifaceted 
form which includes probe and the target sequence. The 
final step was the signal amplification and detection of the 
target mRNA. The target mRNA was sequentially hybridized 
with specific preamplifier, amplifier and label probes. The 
luminescent signal detected is proportionate to the amount 
of target mRNA present in the sample. Target hybridization; 
signal amplification and detection analysis was conducted 
at I-DNA Biotechnology (M) Sdn. Bhd., Malaysia).
STATISTICAL ANALYSIS
Each experiment was carried out in triplicates and the data 
obtained were expressed as the mean±standard deviation. 
Statistical comparisons were conducted using paired-
student t-test and two way analysis of variance (ANOVA) 
test and significance was set at p<0.05.
RESULTS
CELL VIABILITY EFFECT OF ALOE EMODIN AND 
TAMOXIFEN ON MCF-7
The effect of aloe emodin and tamoxifen on the number 
of viable cells in proliferation was examined using trypan 
blue exclusion test. Using MCF-7 IC50 as a reference, 
aloe emodin was found to inhibit the viability of MCF-
7 by 62.86±10.36%, (p<0.05, n=3) while not affecting 
MCF-10A. In contrast, tamoxifen was non-selective as it 
inhibited the viability of both MCF-7 (IC50 of 27 μM) and 
MCF-10A cells (IC50 of 38 μM) by 34.55±15.05% and 
44.50±11.33% (p<0.05, n=3), respectively (Figure 1). 
These results verified our previous findings of aloe emodin 
potential as a selective anti-proliferative agent to ER+-breast 
cancer cells, MCF-7 (Amin et al. 2013). 
*Significant compared with untreated cells, p<0.05; +Significant difference between 
the effect of aloe emodin on MCF-10A viability compared with tamoxifen, p<0.05
FIGURE 1. Aloe emodin and tamoxifen effects on cell viability 
CELL APOPTOSIS EFFECT OF ALOE EMODIN AND 
TAMOXIFEN-TREATED MCF-7
Aloe emodin- and tamoxifen-induced cell death in MCF-7 
cells was investigated using Annexin V-FITC/PI staining. 
The results generated from flow cytometer analysis were 
presented as scatter plots seen in each graph with four 
distinguished regions (Figure 2(a)). Cells residing in the 
upper right (UR) and the lower right (LR) on each side of 
the scatter plots were indicated as late and early apoptosis, 
respectively. Figure 2(a) is the representative findings 
of Annexin V-FITC/PI staining on MCF-7 cells (n=3). The 
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overall percentage of apoptosis obtained from the above 
assay was calculated by combining the percentage of the 
all three sets of UR and LR (Figure 2(b)).
 The apoptotic effect of aloe emodin on MCF-7 was 
clearly seen with the increased population on both UR 
and LR at 72 h of treatment. As indicated in Figure 2(b), 
aloe emodin and tamoxifen induced apoptosis in MCF-7 
by 29.3±0.55% (p<0.05, n=3) and 30.2±0.56% (p<0.05, 
n=3) at 72 h, respectively. It is interesting to note that aloe 
emodin apoptotic activity was similar to tamoxifen. 
ALOE EMODIN AND TAMOXIFEN EFFECT ON IGF-1R, IGFBP-2 
AND B-RAF GENE EXPRESSION IN MCF-7
We sought to study the expression of IGF-1R and 
its downstream genes (IGFBP-2 and B-raf) on both 
aloe emodin- and tamoxifen-treated MCF-7. Three 
housekeeping genes were used i.e. hypoxanthine-guanine 
phosphoribosyltransferase (HPRT), glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) and β-actin. However 
significant differences were only seen after normalizing 
with HPRT. For tamoxifen-treated MCF-7, as expected IGF-
1R and its key signalling components (IGFBP-2 and B-raf) 
were found to be down regulated. The highest changes was 
seen in IGFBP-2 (77%; p<0.05, n=3), followed by IGF-1R 
(75%; p<0.05, n=3) and B-raf (42%; p<0.05, n=3). Aloe 
emodin-treated cells show similar story, down regulation 
of IGF-1R and its downstream target genes. As indicated in 
Figure 3, the highest changes were seen in IGFBP-2 (63%; 
p<0.05, n=3), followed by IGF-1R (53%; p<0.05, n=3), 
B-raf (41%; p<0.05, n=3). Interestingly, aloe emodin was 
as efficient as tamoxifen in down regulating IGFBP-2 and 
B-raf (Figure 3). 
DISCUSSION
Our findings have provided insight view of aloe emodin 
involvement in transducing apoptosis signalling in ER+-
breast cancer cells, MCF-7. Our preliminary study has 
shown that it has selective cytotoxic effect on MCF-7 with 
IC50 of 80 μM, but without affecting control breast cells, 
MCF-10A (Amin et al. 2013). The results from trypan blue 
exclusion test were in concordance with the proliferation 
assay. Consistently, our results were in accordance with 
other cancer cells such as prostate (Lin et al. 2006), 
*Significant compared to untreated cells, p<0.05
FIGURE 2. (b) The percentages of apoptosis induce by aloe emodin 
and tamoxifen on MCF-7 
FIGURE 2. (a) PI and Annexin V-FITC staining of MCF-7 cell apoptosis analysed by Calibur flow cytometry
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hepatoma (Lu et al. 2007) and colon (Suboj et al. 2012). 
Numerous reports investigating the anti-proliferative 
effect of aloe emodin have proposed the importance of 
apoptosis as the mode of death induced in various cancer 
cells (Lin et al. 2006; Lu et al. 2007; Suboj et al. 2012). 
However, its action on ER+-breast cells and in comparison 
with tamoxifen is not well known. Therefore we aimed 
to compare its effect with tamoxifen on ER+-breast cancer 
cells, MCF-7. Using Annexin V-FITC/PI staining, we 
observed the presence early apoptotic and late apoptotic 
cells after 72 h of aloe emodin and tamoxifen treatments 
in MCF-7 as compared to untreated cells. Aloe emodin 
apoptotic activity was similar to tamoxifen.
 Even though the relationship between the aloe emodin 
and apoptosis effect in MCF-7 cells was obvious, little 
knowledge was available on its underlying signalling 
pathways. Since its effects on MCF-7 were similar with 
tamoxifen, we then investigated the pathway that was 
known to be involved in tamoxifen-induced cell death of 
MCF-7. Therefore, we investigated the involvement of IGF-
1R, IGFBP-2 and B-raf genes in aloe emodin-treated cells as 
compared with tamoxifen using QuantiGene 2 Plex Assay. 
This method was favoured compared with a normal real 
time (RT)-PCR as it did not required total RNA purification 
or reverse transcription processes. Thus, by applying direct 
quantification on its biological source, much variability 
introduced by pre-processing samples can be eliminated 
(Ariffin 2013).
 The IGF system has the potential to prevent apoptosis 
by promoting the survival-signal. Once activated by IGFs, 
it stimulated the activation of Ras/Braf/ERKs of MAPK 
cascade and ultimately proliferation (Zhang et al. 2011). 
Clinically, IGF-1R is commonly over expressed in primary 
breast tumors (Foulstone et al. 2013) and phosphorylated in 
all breast cancer subtypes (Law et al. 2008). Its expression 
is fundamental in facilitating cell survival and metastasis in 
breast neoplastic cell lines (Sachdev et al. 2010). IGF-IR and 
ERα are co-expressed in ER+-breast tumours. Moreover, 
estrogens stimulate the expression of IGF-IR; while anti-
estrogen such as tamoxifen down regulate its signalling 
(Surmacz 2000). It is up regulated in tamoxifen-resistant 
breast cancer cells (Massarweh et al. 2008). The elevation 
of IGFBP-2 expression has also been associated with 
breast tumor (So et al. 2008). Observation using clinical, 
in vivo and in vitro breast cancer samples, have found 
that the expression of IGFBP-2 was higher comparing to 
benign samples (So et al. 2008). The expression of both 
IGFBP-2 and IGF-1R were much related as the exogenous 
action of IGFBP-2 on ERα in breast cancer cells was via the 
involvement of IGF-1R and activation of PI3K (Foulstone et 
al. 2013). Similarly to tamoxifen, we observed that IGF-1R, 
IGFBP-2 and B-raf gene expressions were down regulated 
in aloe emodin-treated MCF-7. Thus, we believed that aloe 
emodin has potential as an inhibitor in the drug therapy 
targeting through the IGFs pathway. However, further 
research on mRNA and protein expressions in vivo and in 
vitro are required to gain more information on the inter- and 
intra-relationship of these target genes.
CONCLUSION
In conclusion, we found that aloe emodin selectively 
inhibited the proliferation ER+-breast cancer cells, MCF-
7, but not control breast cells, MCF-10A. In contrary, 
tamoxifen inhibited both cell proliferations. Interestingly, 
aloe emodin induced apoptosis in MCF-7 through similar 
pathway as tamoxifen i.e., down regulation of IGF-1R, 
IGFBP-2 and B-raf. These findings suggested aloe emodin 
can be used in combination with tamoxifen to enhance its 
efficacy in ER+-breast cancer treatment. These findings 
*Significant compared to untreated cells, p<0.05; Significant difference between the expressions of IGF-1R in 
aloe emodin treatment group compared to tamoxifen, p<0.05; Significant difference between the expressions of 
IGFBP-2 in aloe emodin treatment group compared to tamoxifen, p<0.05
FIGURE 3. The graph showed the expression of genes in MCF-7 after treatment with aloe 
emodin and tamoxifen at their respective IC50 against untreated cells 
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might be a good baseline for further investigation in this 
particular research.
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